NCT05047601

Brief Summary

The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection. All participants in the study will receive treatment for COVID-19 as needed, based on their regular doctor's recommendation. Two-thirds of participants will also receive two study medicines (PF-07321332 and ritonavir) by mouth twice a day for either five or ten days. We will compare the experiences of people receiving the study medicines to those of the people who do not. This will help us determine if the study medicines are safe and effective

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
2,954

participants targeted

Target at P75+ for phase_2 covid19

Timeline
Completed

Started Sep 2021

Geographic Reach
17 countries

170 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 1, 2021

Completed
8 days until next milestone

Study Start

First participant enrolled

September 9, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 17, 2021

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 12, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 12, 2022

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

May 6, 2023

Completed
Last Updated

May 6, 2023

Status Verified

April 1, 2023

Enrollment Period

7 months

First QC Date

September 1, 2021

Results QC Date

April 11, 2023

Last Update Submit

April 11, 2023

Conditions

Keywords

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)

Outcome Measures

Primary Outcomes (1)

  • Percentage of Participants Who Developed Symptomatic RT-PCR or RAT Confirmed SARS-CoV-2 Infection Through Day 14: Among Participants With Negative RT-PCR at Baseline

    Percentage of participants who developed symptomatic Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) or Rapid Antigen Test (RAT) confirmed SARS-Cov-2 infection were reported in this outcome measure. Index case was defined as participants with symptomatic COVID-19.

    From Day 1 to Day 14

Secondary Outcomes (15)

  • Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation

    From start of study intervention (Day 1) up to end of safety follow-up (Day 38)

  • Percentage of Participants Who Developed Symptomatic RT-PCR or RAT Confirmed SARS-CoV-2 Infection Through Day 14: Among Participants With Negative RT-PCR at Baseline With Increased Risk of Severe COVID-19 Illness

    From Day 1 to Day 14

  • Percentage of Participants With COVID-19 Related Hospitalization or Death From Any Cause Through Day 28: Among Participants With Negative RT-PCR at Baseline With Increased Risk of Severe COVID-19 Illness

    From Day 1 to Day 28

  • Percentage of Participants With Asymptomatic RT-PCR or RAT Confirmed SARS-CoV-2 Infection Through Day 14: Among Participants With Negative RT-PCR at Baseline

    From Day 1 to Day 14

  • Time to RT-PCR or RAT Confirmed SARS-CoV-2 Infection Through Day 14: Among Participants With Negative RT-PCR at Baseline

    From Day 1 to Day 14

  • +10 more secondary outcomes

Study Arms (3)

PF-07321332/ritonavir (5 days)

EXPERIMENTAL

Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 5 followed by Placebo every 12 hours from Day 6 through Day 10

Drug: PF-07321332Drug: Placebo for PF-07321332Drug: Placebo for RitonavirDrug: Ritonavir

PF-07321332/ritonavir (10-Day)

EXPERIMENTAL

Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 10.

Drug: PF-07321332Drug: Ritonavir

Placebo

PLACEBO COMPARATOR

Participants will receive placebo every 12 hours from Day 1 through Day 10.

Drug: Placebo for PF-07321332Drug: Placebo for Ritonavir

Interventions

PF-07321332

PF-07321332/ritonavir (10-Day)PF-07321332/ritonavir (5 days)

Placebo

PF-07321332/ritonavir (5 days)Placebo

Placebo

PF-07321332/ritonavir (5 days)Placebo

Ritonavir

PF-07321332/ritonavir (10-Day)PF-07321332/ritonavir (5 days)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants who have a negative screening SARS-CoV-2 rapid antigen test result and who are asymptomatic household contacts with exposure within 96 hours to an individual who is symptomatic and recently tested positive for SARS CoV-2.
  • Fertile participants must agree to use a highly effective method of contraception

You may not qualify if:

  • History of SARS-CoV-2 infection in the past 6 months
  • Experiencing measured fever (documented temperature \>38˚C or 100.4˚F) or other signs or symptoms consistent with COVID-19
  • Known medical history of active liver disease
  • Chronic Kidney Disease or have known moderate to severe renal impairment.
  • Known Human Immunodeficiency Virus (HIV) infection with viral load \> 400 copies/ml within the last 6 months or taking prohibited medications for HIV treatment
  • Suspected or confirmed concurrent active systemic infection
  • Active cancer requiring treatment with prohibited medication.
  • Current or expected use of any medications or substances that are highly dependent on Cytochrome P450 3A4 (CYP3A4) for clearance or are strong inducers of CYP3A4
  • Has received approved, authorized, or investigational anti-SARS-CoV-2 mAb, convalescent plasma, other drugs for treatment of COVID-19, or other anti-SARS-CoV-2 biologic products within 6 months of screening
  • Has received any SARS-CoV-2 vaccine within 6 months prior to screening or is expected to receive a SARS-CoV-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments through Day 38.
  • Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19
  • Known or prior participation in this trial or another trial involving PF-07321332.
  • Females who are pregnant or breastfeeding.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (170)

Cahaba Research Inc

Pelham, Alabama, 35124, United States

Location

The Institute for Liver Health dba Arizona Clinical Trials

Tucson, Arizona, 85712, United States

Location

Ascada Health PC

Fullerton, California, 92835, United States

Location

Optimus Medical Group

San Francisco, California, 94102, United States

Location

Synergy Healthcare

Bradenton, Florida, 34208, United States

Location

MOORE Clinical Research, Inc.

Brandon, Florida, 33511, United States

Location

TrueBlue Clinical Research

Brandon, Florida, 33511, United States

Location

Herco Medical and Research Center Inc

Coral Gables, Florida, 33134, United States

Location

Advance Clinical Research Group

Cutler Bay, Florida, 33157, United States

Location

Beautiful Minds Clinical Research Center

Cutler Bay, Florida, 33157, United States

Location

Qway Research

Hialeah, Florida, 33010, United States

Location

Eastern Research Inc

Hialeah, Florida, 33013, United States

Location

Inpatient Research Clinic

Hialeah, Florida, 33013, United States

Location

Doral Medical Research,LLC

Hialeah, Florida, 33016, United States

Location

Unlimited Medical Research Group, LLC

Hialeah Gardens, Florida, 33018, United States

Location

ASCLEPES Research Centers

Lutz, Florida, 33549, United States

Location

Angels Clinical Research Institute

Miami, Florida, 33122, United States

Location

LCC Medical Research Institute, LLC

Miami, Florida, 33126, United States

Location

Premium Medical Research Corp

Miami, Florida, 33126, United States

Location

Global Health Clinical Trials Corp

Miami, Florida, 33135, United States

Location

South Florida Research Center, Inc.

Miami, Florida, 33135, United States

Location

University of Miami Health System

Miami, Florida, 33136, United States

Location

I.V.A.M. Clinical & Investigational Center, LLC

Miami, Florida, 33144, United States

Location

Medical Research of Westchester Inc

Miami, Florida, 33165, United States

Location

C'A Research

Miami, Florida, 33174, United States

Location

ProLive Medical Research, Corp.

Miami, Florida, 33175, United States

Location

Entrust Clinical Research

Miami, Florida, 33176, United States

Location

Reed Medical Research

Miami, Florida, 33176, United States

Location

Kendall South Medical Center, Inc.

Miami, Florida, 33185, United States

Location

Clinical Site Partners, Inc dba CSP Miami

Miami, Florida, 33186, United States

Location

Coral Research Clinic Corp

Miami, Florida, 33186, United States

Location

Pro-Care Research Center, Corp.

Miami Gardens, Florida, 33014, United States

Location

Savin Medical Group, LLC

Miami Lakes, Florida, 33014, United States

Location

Omega Research Orlando

Orlando, Florida, 32808, United States

Location

NAPA Research LLC

Pompano Beach, Florida, 33064, United States

Location

CDC Research Institute, LLC

Port Saint Lucie, Florida, 34952, United States

Location

USPA Advance Concept Medical Research Group LLC

South Miami, Florida, 33143, United States

Location

ASCLEPES Research Centers

Spring Hill, Florida, 34609, United States

Location

GCP, Global Clinical Professionals

St. Petersburg, Florida, 33705, United States

Location

Sunrise Research Institute

Sunrise, Florida, 33325, United States

Location

Santos Research Center, CORP

Tampa, Florida, 33615, United States

Location

Research by Design, LLC

Chicago, Illinois, 60643, United States

Location

Accellacare

Ames, Iowa, 50010, United States

Location

McFarland Clinic, PC

Ames, Iowa, 50010, United States

Location

Southern Clinical Research Associates. LLC

Metairie, Louisiana, 70001, United States

Location

Meridian Clinical Research, LLC

Grand Island, Nebraska, 68803, United States

Location

Quality Clinical Research Inc

Omaha, Nebraska, 68112, United States

Location

Quality Clinical Research

Omaha, Nebraska, 68114, United States

Location

Walmart

Las Vegas, Nevada, 89108, United States

Location

Excel Clinical research

Las Vegas, Nevada, 89109, United States

Location

Walgreens

Las Vegas, Nevada, 89121, United States

Location

NYC Health + Hospitals / Harlem

New York, New York, 10037, United States

Location

Monroe Biomedical Research

Monroe, North Carolina, 28112, United States

Location

Innovo Research: Wilmington Health

Wilmington, North Carolina, 28401, United States

Location

PharmaTex Research, LLC

Amarillo, Texas, 79109, United States

Location

Conroe Willis Medical Research

Conroe, Texas, 77304, United States

Location

South Texas Clinical Research

Corpus Christi, Texas, 78413, United States

Location

SingnatureCare Emergency Center

Houston, Texas, 77008, United States

Location

Trio Clinical Trials, LLC

Houston, Texas, 77008, United States

Location

C & R Research Services USA

Houston, Texas, 77022, United States

Location

SMS Clinical Research, LLC

Mesquite, Texas, 75149, United States

Location

Epic Medical Research

Red Oak, Texas, 75154, United States

Location

Sun Research Institute

San Antonio, Texas, 78215, United States

Location

Tranquility Research

Webster, Texas, 77598, United States

Location

Instituto de Investigaciones Clinicas Zarate

Zárate, Buenos Aires, B2800DGH, Argentina

Location

Instituto Médico de la Fundación Estudios Clínicos (Fundación Estudios Clínicos)

Rosario, Santa Fe Province, 2000, Argentina

Location

Pesquisare Saude S/S Ltda

Santo André, São Paulo, 09080-110, Brazil

Location

Conjunto Hospitalar do Mandaqui

São Paulo, 02401-400, Brazil

Location

"Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases-Haskovo" Ltd

Haskovo, 6300, Bulgaria

Location

MHAT "Sv.Ivan. Rilski'' Kozloduy EOOD

Kozloduy, 3320, Bulgaria

Location

Diagnostic-Consultative Center I Lom EOOD

Lom, 3600, Bulgaria

Location

Multiprofile Hospital for Active Treatment- Sveti Nikolay Chudotvoretz EOOD

Lom, 3600, Bulgaria

Location

Medical centre Leo Clinic EOOD

Lovech, 5500, Bulgaria

Location

MHAT Heart and Brain EAD

Pleven, 5800, Bulgaria

Location

DCC Sveti Georgi EOOD

Plovdiv, 4000, Bulgaria

Location

MHAT "St. Panteleimon "- Plovdiv

Plovdiv, 4004, Bulgaria

Location

UMHAT Medica Ruse OOD

Rousse, 7013, Bulgaria

Location

Multiprofile Hospital for Active Treatment - Samokov EOOD

Samokov, 2000, Bulgaria

Location

Multiprofile hospital for active treatment - Sliven to Military Medical Academy

Sliven, 8800, Bulgaria

Location

Diagnostic-Consultative Center XXII- Sofia ЕООD

Sofia, 1113, Bulgaria

Location

UMHATEM N. I. Pirogov EAD

Sofia, 1606, Bulgaria

Location

Specialized hospital for active treatment in pulmonology and phthisiology "Stara Zagora" EOOD

Stara Zagora, 6000, Bulgaria

Location

Medical center Leo Clinic EOOD

Varna, 9020, Bulgaria

Location

MOBAL "D-r Stefan Cherkezov" AD

Veliko Tarnovo, 5002, Bulgaria

Location

Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases Vratsa EOOD

Vratsa, 3000, Bulgaria

Location

Clinica de la Costa LTDA.

Barranquilla, Atlántico, 080020, Colombia

Location

Caimed S.A.S.

Yopal, Casanare Department, 850001, Colombia

Location

Cireem Sas

Bogota, Cundinamarca, 110221, Colombia

Location

Doktor Brno s.r.o.

Brno, 602 00, Czechia

Location

Zdraví-Fit, s.r.o.

Protivín, 398 11, Czechia

Location

Nemocnice Slany

Slaný, 274 01, Czechia

Location

Medifarma-98 Kft.

Nyíregyháza, 4400, Hungary

Location

International University of Health and Welfare Narita Hospital

Narita, Chiba, 286-8520, Japan

Location

Rakuwakai Otowa Hospital

Kyoto, Kyoto, 607-8062, Japan

Location

Rinku General Medical Center

Izumisano, Osaka, 598-8577, Japan

Location

Denenchofu Family Clinic

Ōta-ku, Tokyo, 145-0071, Japan

Location

Sekino Hospital

Toshimaku, Tokyo, 171-0014, Japan

Location

Hospital Miri

Miri, Sarawak, 98000, Malaysia

Location

Clinical Research Institute Saltillo S.A. de C.V.

Saltillo, Coahuila, 25020, Mexico

Location

InfectoLab Consultorios de Especialidad en Infectologia

Tijuana, Estado de Baja California, 22010, Mexico

Location

Instituto Jalisciense de Metabolismo, S.C.

Guadalajara, Jalisco, 44670, Mexico

Location

Christus- Latam Hub Center of Excellence and Innovation Center S.C.

Monterrey, Nuevo León, 64060, Mexico

Location

Eukarya Pharmasite S.C.

Monterrey, Nuevo León, 64718, Mexico

Location

EME RED Hospitalaria

Mérida, Yucatán, 97000, Mexico

Location

Instituto de Investigaciones Clinicas para la Salud A.C.

Durango, 34000, Mexico

Location

FAICIC Clinical Research

Veracruz, 91900, Mexico

Location

Sociedad de Metabolismo y Corazon S.C.

Veracruz, 91900, Mexico

Location

Centrum Badań Klinicznych Piotr Napora Lekarze Spółka Partnerska

Wroclaw, 51-162, Poland

Location

Kirovsk Interdistrict Hospital

Kirovsk, Leningradskaya Oblast', 187342, Russia

Location

LLC Trekhgorka Medicine

Odintsovo, Moscow Oblast, 143005, Russia

Location

Clinica UZI 4D

Pyatigorsk, Stavropol Kray, 357502, Russia

Location

Barnaul City Hospital Number 5

Barnaul, 656045, Russia

Location

Korolev Medicine

Korolyov, 141070, Russia

Location

KDC "Evromedservis", OJSC

Moscow, 115419, Russia

Location

City Polyclinic #44

Saint Petersburg, 192071, Russia

Location

City Polyclinic No. 109

Saint Petersburg, 192298, Russia

Location

LLC Strategic Medical Systems

Saint Petersburg, 194291, Russia

Location

City Out-patient clinic #112

Saint Petersburg, 195427, Russia

Location

"Research Center Eco-safety" LLC

Saint Petersburg, 196143, Russia

Location

LLC Kurator

Saint Petersburg, 196240, Russia

Location

Saint-Petersburg State Budgetary Healthcare Institution "City Pokrovskaya hospital"

Saint Petersburg, 199106, Russia

Location

City Out-patient clinic #4

Saint Petersburg, 199406, Russia

Location

Smolensk State Medical University

Smolensk, 214019, Russia

Location

LLC Family clinic

Yekaterinburg, 620109, Russia

Location

MERC Welkom

Welkom, Free State, 9460, South Africa

Location

Worthwhile Clinical Trials

Benoni, Gauteng, 1500, South Africa

Location

LCS Clinical Research

Johannesburg, Gauteng, 1868, South Africa

Location

Peermed CTC (Pty) Ltd T/A MERC Kempton

Kempton Park, Gauteng, 1619, South Africa

Location

Global Clinical Trials

Pretoria, Gauteng, 0001, South Africa

Location

Botho Ke Bontle Health Services

Pretoria, Gauteng, 0122, South Africa

Location

About Allergy (PTY) Ltd

Pretoria, Gauteng, 0181, South Africa

Location

Into Research

Pretoria, Gauteng, 0181, South Africa

Location

Clinical Trial Systems (Pty) Ltd

Pretoria, Gauteng, 0186, South Africa

Location

Sandton Medical Clinic

Sandton, Gauteng, 2196, South Africa

Location

Synapta Clinical Research Center

Durban, KwaZulu-Natal, 4001, South Africa

Location

Dr PJ Sebastian Clinical Research Centre

Durban, KwaZulu-Natal, 4092, South Africa

Location

Ahmed Al-Kadi Private Hospital

Mayville, Durban, KwaZulu-Natal, 4091, South Africa

Location

Limpopo Clinical Research Initiative

Thabazimbi, Limpopo, 0380, South Africa

Location

NHC Thohoyandou CRS

Thohoyandou, Limpopo, 0950, South Africa

Location

MERC Middelburg

Middelburg, Mpumalanga, 1055, South Africa

Location

Madibeng Centre for Research

Brits, North West, 0250, South Africa

Location

FCRN Clinical Trial Centre

Vereeniging, 1935, South Africa

Location

Complexo Hospitalario Universitario da Coruna

A Coruña, 15006, Spain

Location

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),

Pathumwan, Bangkok, 10330, Thailand

Location

Faculty of Medicine - Khon Kaen University

Muang, Changwat Khon Kaen, 40002, Thailand

Location

King Chulalongkorn Memorial Hospital

Bangkok, 10330, Thailand

Location

Faculty of Tropical Medicine, Mahidol University

Bangkok, 10400, Thailand

Location

Tropical Medicine Hospital

Bangkok, 10400, Thailand

Location

Ankara University Medical Faculty, Ibni-Sina Hospital

Ankara, 06230, Turkey (Türkiye)

Location

Istanbul University Istanbul Medical Faculty

Fatih / Istanbul, 34093, Turkey (Türkiye)

Location

Gaziantep Universitesi Tip Fakultesi Sahinbey Uygulama ve Arastirma Hastanesi

Gaziantep, 27310, Turkey (Türkiye)

Location

Acibadem University Atakent Hospital

Istanbul, 34303, Turkey (Türkiye)

Location

Izmir Suat Seren Chest Disease and Surgery Training and Research Hospital

Izmir, 35110, Turkey (Türkiye)

Location

Mersin University Medical Faculty

Mersin, 33110, Turkey (Türkiye)

Location

Karadeniz Teknik Universitesi Farabi Hastanesi

Trabzon, 61080, Turkey (Türkiye)

Location

Regional Communal Nonprofit Institution "Chernivtsi Regional Clinical Hospital"

Chernivtsi, 58001, Ukraine

Location

Communal non-commercial Enterprise "City Central Clinical Hospital" of Chernivtsi City Council

Chernivtsi, 58002, Ukraine

Location

Communal non-profit enterprise "City Clinical Hospital #16" of Dnipro City Council

Dnipro, 49069, Ukraine

Location

Communal nonprofit enterprise "Central City Clinical Hospital of Ivano-Frankivsk City Council"

Ivano-Frankivsk, 76018, Ukraine

Location

Municipal Non-profit Enterprise "Ivano-Frankivsk Regional Phthisiopulmonology Center of

Ivano-Frankivsk, 76018, Ukraine

Location

Municipal Nonprofit Enterprise "City Student Hospital" of Kharkiv City Council

Kharkiv, 61002, Ukraine

Location

Municipal Nonprofit Enterprise of Kharkiv Regional Council "Regional Clinical Infectious Diseases

Kharkiv, 61096, Ukraine

Location

Municipal Nonprofit Enterprise "City Clinic Hospital # 13" of Kharkiv City Council

Kharkiv, 61124, Ukraine

Location

Polyclinic of Center for Medical Services and Rehabilitation of State Joint-Stock Holding Company

Kyiv, 04050, Ukraine

Location

Municipal Nonprofit Enterprise "Lviv City Clinic Hospital #4"

Lviv, 79005, Ukraine

Location

Municipal NonProfit Enterprise of the Lviv Regional Council Lviv Regional Information and Analytical

Lviv, 79008, Ukraine

Location

Municipal Nonprofit Enterprise "Lviv City Clinic Hospital #4"

Lviv, 79011, Ukraine

Location

Municipal Enterprise "Poltava Regional Clinical Infectious Diseases Hospital" of Poltava Regional

Poltava, 36011, Ukraine

Location

Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council

Tarasove Village, 45625, Ukraine

Location

Communal Enterprise "Hospital #1" of Zhytomyr City Council

Zhytomyr, 10002, Ukraine

Location

Related Publications (1)

  • Hammond J, Yunis C, Fountaine RJ, Luscan G, Burr AM, Zhang W, Wisemandle W, Soares H, Baniecki ML, Hendrick VM, Kalfov V, Pypstra R, Rusnak JM. Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2024 Jul 18;391(3):224-234. doi: 10.1056/NEJMoa2309002.

Related Links

MeSH Terms

Conditions

COVID-19

Interventions

nirmatrelvirRitonavir

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

ThiazolesSulfur CompoundsOrganic ChemicalsAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Results Point of Contact

Title
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer Inc.

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Double Blind Double Dummy
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Eligible participants who are asymptomatic household contacts of an individual with symptomatic COVID-19 will be randomized (1:1:1) to receive orally every 12 hours: PF-07321332/ritonavir for 5 days followed by placebo for 5 days or PF-07321332/ritonavir for 10 days or Placebo for 10 days
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 1, 2021

First Posted

September 17, 2021

Study Start

September 9, 2021

Primary Completion

April 12, 2022

Study Completion

April 12, 2022

Last Updated

May 6, 2023

Results First Posted

May 6, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will share

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

More information

Locations